The high prevalence of the EGFR protein overexpression in SCCHN makes this a logical therapeutic target, and many studies have shown EGFR monoclonal antibodies (MoAbs) to be more active than small molecule tyrosine kinase inhibitors in this disease. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.